[ad_1]
(RTTNews) – Radiopharm Theranostics Limited (RAD.AX) announced it received a strategic investment from Lantheus Holdings Inc. (LNTH) totaling up to A$18 million.
Lantheus has agreed to make an initial equity investment of A$7.5 million or US$4.99 million and will have an option to invest a further A$7.5 million or US$5 million within 6 months on the same terms.
Additionally, Radiopharm has agreed to transfer two of its early preclinical assets to Lantheus for A$3.0 million or US$2.0 million pursuant to a separate transfer and development agreement.
Radiopharm said it will use the net proceeds of Lantheus’ investment for drug manufacturing, clinical trials and general working capital.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
[ad_2]
Source link